Clinical trial of ginsenoside Rh2 combined with concurrent radiotherapy and chemotherapy in the treatment of patients with nasopharyngeal carcinoma
10.13699/j.cnki.1001-6821.2017.23.037
- VernacularTitle:人参皂苷Rh2联合同步放化疗治疗鼻咽癌的临床研究
- Author:
Cheng GONG
1
;
Liang-Bo LI
;
Yong LIAO
;
Jun-Wu TAN
;
Xue-Qiu CAO
Author Information
1. 湖北民族学院附属民大医院耳鼻咽喉头颈外科,湖北恩施445000
- Keywords:
nasopharyngeal cancer;
ginsenoside Rh2;
concurrent radiotherapy and chemotherapy;
survival rate
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(23):2449-2451
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of ginsenoside Rh2 combined with concurrent radiotherapy and chemotherapy in the treatment of nasopharyngeal carcinoma.Methods A total of 123 cases of non-keratinized undifferentiated nasopharyngeal carcinoma (stage Ⅲ-Ⅳ A) were divided into treatment group (n =63 cases) and control group (n =60 cases).Control group was received concurrent radiotherapy and chemotherapy and conventional symptomatic support therapy,6MV X radiation,the original lesion dose of 66-76 Gy,lymph node metastasis treated with 60-70 Gy,56-60 Gy of neck prevention,5 times a week;intravenous infusion of cisplatin 30 mg · m-2,once a week.Treatment group was orally administration of ginsenoside Rh2 250 mg on the basis of control group.The two groups were treated for 6 weeks.The short-term efficacy was evaluated by reference to the sohd tumor evaluation criteria (RECIST).The overall survival rate was followed for 2 years.The safety evaluation was conducted according to the World Health Organization (WHO) evaluation criteria for adverse drug resistance.Results After treatment,the objective response rates in treatment group and control group were 95.24％ (60 cases/63 cases),78.33％ (14 cases/60 cases),with significant difference (P ＜0.05).The disease control rates in treatment group and control group were 98.41％ (62 cases/63 cases),93.33％ (56 cases/60 cases),with significant difference (P＜0.05).The overall survival rates in treatment group and control group were 90.48％ (57 cases/63 cases),76.67％ (46 cases/60 cases),with significant difference (P ＜0.05).The incidences of adverse reactions in treatment group and control group were 39.68％,58.33％,with significant difference (P ＜ 0.05).Conclusion The clinical efficacy and safety of ginsenoside Rh2 combined with concurrent radiotherapy and chemotherapy in the treatment of nasopharyngeal carcinoma were better than those of simple concurrent radiotherapy and chemotherapy.
